Why Compounding Access Is Not an Established Path Positioning in the Metabolic Medicine Conversation For physicians fielding patient questions about 5-amino-1MQ, the appropriate framing: Promising mechanism with solid preclinical rationale Early clinical development human efficacy and safety not yet well characterized No legitimate clinical access pathway in the United States as of 2026 Alternative evidence-based options exist for the underlying metabolic optimization goals patients typically pursue Key Takeaways 5-amino-1MQ is a small-molecule NNMT inhibitor, not a peptide
Glutathione usually takes longer - often 2-3 months before you see significant changes in skin tone
doi:10.1016/j.biochi.2016.02.012 [PubMed] [Elsevier] Hanna M, Jaqua E, Nguyen V, Clay J
This group has also recently reported (2025) that intravenous administration of BPC 157 had no side-effects and was well-tolerated in two women
I can't tell you how many cans of cat food I've binned
Importantly, oxidative stress and glutathione deficits have also been implicated in depression, bipolar disorder, and schizophreniabroadening their potential impact across mental health care